「news」の検索結果
74件：21～25件目を表示
-
Data And Statistics | About Senju | SENJU Pharmaceutical
Sales Revenue. Operating Profit and Ordinary Profit 2020.3 2021.3 2022.3* 2023.3* 2024.3* Sales Revenue 41.2 40.7 40.8 46.4 48.9 Operating Profit 2.2 5.4 6.9 7.4 7.1 Ordinary Profit 4.3 8.0 9.1 8.7 9.
https://www.senju.co.jp/english/about/sales.html -
Mytear EYETECT ALPITATTO | OTC Products, etc. | Products | SENJU Pharmaceutical
This medicine is recommended for people who have continuing allergy symptoms with inflammation. Category 2 OTC medicines Mytear® EYETECT® ALPITATTO Works on unpleasant eye itching due to pollens and o
https://www.senju.co.jp/english/products/ap.html -
R&D Pipeline | Research & Development | SENJU Pharmaceutica
PROGRESS OF DEVELOPMENT Disclosuring of information after Phase 1 DrugIndicationStatus (Region) Difluprednateinflammation associated with ocular surgery, UveitisApproved (Russia) Pranoprofeninflammati
http://www.senju.co.jp/english/rd/pipeline.html -
Compliance System | Our Initiatives for Society/Environment | About Senju | SENJU Pharmaceutical
Code of Conduct for Compliance The directors, employees and other members of Senju Pharmaceutical Co., Ltd. (“SENJU”) will act in compliance not only with the law but will operate under a high standar
https://www.senju.co.jp/english/about/csr03.html -
NewMytear CL Ice Refresh | OTC Products, etc. | Products | SENJU Pharmaceutical
Category 3 OTC medicines New Mytear® CL Ice Refresh Nice and comfortable feeling lasting a long time *Powerfully cool CHARACTERISTICS This medicine can be used while wearing all types of contact lense
https://www.senju.co.jp/english/products/mytearir.html